bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer
Authors: Li Tuan-Jie , Jiang Yu-Ming , Hu Yan-Feng , Huang Lei , Yu Jiang , Zhao Li-Ying , Deng Hai-Jun , Mou Ting-Yu , Liu Hao , Yang Yang , Zhang Qi , Li Guo-Xin
Published: April 2023

The accumulation of neutrophils in the invasive margin and IL-17 expression predicts reduced survival in GC patients. 245 paraffin-embedded GC samples were stained with an anti-CD66b Ab. The patients were divided into two groups according to the median CD66b+ neutrophil density. Overall survival and progression-free survival of 245 patients; High infiltration of neutrophils in the invasive margin was associated with reduced survival in different TNM stages. Cumulative overall and progression-free survival time were calculated using the Kaplan-Meier method and analyzed by the log-rank test (A). Kaplan-Meier analysis of progression-free survival and overall survival stratified by IL-17 expression in GC patients (B).
SI Table 2 from Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
Authors: Song Kyung-A , Niederst Matthew J. , Lochmann Timothy L. , Hata Aaron N. , Kitai Hidenori , Ham Jungoh , Floros Konstantinos V. , Hicks Mark A. , Hu Haichuan , Mulvey Hillary E. , Drier Yotam , Heisey Daniel A.R. , Hughes Mark T. , Patel Neha U. , Lockerman Elizabeth L. , Garcia Angel , Gillepsie Shawn , Archibald Hannah L. , Gomez-Caraballo Maria , Nulton Tara J. , Windle Brad E. , Piotrowska Zofia , Sahingur Sinem E. , Taylor Shirley M. , Dozmorov Mikhail , Sequist Lecia V. , Bernstein Bradley , Ebi Hiromichi , Engelman Jeffrey A. , Faber Anthony C.
Published: April 2023

ZEB1 binding sites found in 1975R2 cells compared to 1975 parental cells
Supplementary Figure S1 from Noninvasive Detection of Metastases and Follicle Density in Ovarian Tissue Using Full-Field Optical Coherence Tomography
Authors: Peters Inge T.A. , Stegehuis Paulien L. , Peek Ronald , Boer Florine L. , van Zwet Erik W. , Eggermont Jeroen , Westphal Johan R. , Kuppen Peter J.K. , Trimbos J. Baptist , Hilders Carina G.J.M. , Lelieveldt Boudewijn P.F. , van de Velde Cornelis J.H. , Bosse Tjalling , Dijkstra Jouke , Vahrmeijer Alexander L.
Published: April 2023

Proposed clinical workflow for screening cortical ovarian strips prior to autotransplantation in order to minimize the likelihood of reintroducing tumor cells and maximize the likelihood of restoring ovarian function. The light-gray shaded boxes indicate steps in which FF-OCT imaging can provide added value.
Supplementary Figures from PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Authors: Sai Jiqing , Owens Philip , Novitskiy Sergey V. , Hawkins Oriana E. , Vilgelm Anna E. , Yang Jinming , Sobolik Tammy , Lavender Nicole , Johnson Andrew C. , McClain Colt , Ayers Gregory D. , Kelley Mark C. , Sanders Melinda , Mayer Ingrid A. , Moses Harold L. , Boothby Mark , Richmond Ann
Published: April 2023

Supplementary Figure 1: BKM120 inhibited CD4+ T cell, not CD8+ T cell proliferation and had small effects on PyMT specific T cell mediated cytotoxicity only at a 1:50 E/T cell ratio. Supplementary Figure 2: Tumors were initiated as described in Figure 1 and BKM120 was delivered to PyMT-tumor bearing C57Bl/6 mice (n = 5) for different periods of time. Supplementary Figure 3C and 3D. Additional Flow Cytometry Analysis of Leukocyte populations in PD-1 treated animals. Supplementary Figure 3E and 3F. Myeloid FACS analysis and FoxP3 histology from BKM-120 and â�ºPD-1 treated PyMT Supplemental Figure 5: Implantation of expanded human T cells into NSG mice. Supplemental Figure 7: Effects of Loss of PI3KÎ³ on Leukocytes
supplemental legend from Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
Authors: Miyoshi Tomohiro , Umemura Shigeki , Matsumura Yuki , Mimaki Sachiyo , Tada Satoshi , Makinoshima Hideki , Ishii Genichiro , Udagawa Hibiki , Matsumoto Shingo , Yoh Kiyotaka , Niho Seiji , Ohmatsu Hironobu , Aokage Keiju , Hishida Tomoyuki , Yoshida Junji , Nagai Kanji , Goto Koichi , Tsuboi Masahiro , Tsuchihara Katsuya
Published: April 2023

supplemental legend
Supplementary Tables from Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
Authors: Miyoshi Tomohiro , Umemura Shigeki , Matsumura Yuki , Mimaki Sachiyo , Tada Satoshi , Makinoshima Hideki , Ishii Genichiro , Udagawa Hibiki , Matsumoto Shingo , Yoh Kiyotaka , Niho Seiji , Ohmatsu Hironobu , Aokage Keiju , Hishida Tomoyuki , Yoshida Junji , Nagai Kanji , Goto Koichi , Tsuboi Masahiro , Tsuchihara Katsuya
Published: April 2023

Supplementary Table 1- List of the 244 cancer related genes of the target capturing panel Supplementary Table 2 - The coverage statistics for each sample of large cell neuroendocrine carcinoma (LCNEC) Supplementary Table 3 - The coverage statistics for each sample of advanced small cell lung cancer (SCLC) Supplementary Table 4 - Validation of the mutations detected in this study using the Oncomine® Cancer Research Panel (OCP) Supplementary Table 5- Primer Sequences: Sanger Sequencing Supplementary Table 6 - Antibody for immunohistochemical staining Supplementary Table 7 - Candidate somatic mutations of large cell neuroendocrine carcinoma (LCNEC) Supplementary Table 8 - Candidate somatic mutations in advanced small cell lung cancer (SCLC) Supplementary table 9 - Hotspot mutations detected in small cell lung cancer (SCLC) Supplementary Table 10- Variant frequency of candidate somatic mutations of large cell neuroendocrine carcinoma (LCNEC) combined with non-small cell lung cancer (NSCLC) Supplementary Table 11- Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) analysis for the top six most frequently mutated genes in large cell neuroendocrine carcinoma (LCNEC)
Supplementary Table 1 from Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine
Authors: Husain Hatim , Melnikova Vladislava O. , Kosco Karena , Woodward Brian , More Soham , Pingle Sandeep C. , Weihe Elizabeth , Park Ben Ho , Tewari Muneesh , Erlander Mark G. , Cohen Ezra , Lippman Scott M. , Kurzrock Razelle
Published: April 2023

Urine volumes, DNA concentrations, DNA input amounts, the number of output mutant sequencing reads, mutant copies detected and the 95% Confidence Intervals
Supplementary Figure 1 from Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions
Authors: Tak Won Young , Lin Shi-Ming , Wang Yijun , Zheng Jiasheng , Vecchione Aldo , Park Soo Young , Chen Min Hua , Wong Stephen , Xu Ruocai , Peng Cheng-Yuan , Chiou Yi-You , Huang Guan-Tarn , Cai Jianqiang , Abdullah Basri Johan Jeet , Lee June Sung , Lee Jae Young , Choi Jong-Young , Gopez-Cervantes Julieta , Sherman Morris , Finn Richard S. , Omata Masao , O'Neal Michael , Makris Lukas , Borys Nicholas , Poon Ronnie , Lencioni Riccardo
Published: April 2023

Supplementary Figure 1: Computational Modeling Study.
Supplementary Figure 7. RET expression in TCGA datasets. from RET Signaling in Prostate Cancer
Authors: Ban Kechen , Feng Shu , Shao Longjiang , Ittmann Michael
Published: April 2023

Expression RET in TCGA datasets as analyzed in cBioportal. Blue dots are tumors with no mutations. Note that mutations are uncommon in all tumor types. Open dots are from TCGA analyses that were not sequenced.
Supplementary Table 5 from Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
Authors: Rekhtman Natasha , Pietanza Maria C. , Hellmann Matthew D. , Naidoo Jarushka , Arora Arshi , Won Helen , Halpenny Darragh F. , Wang Hangjun , Tian Shaozhou K. , Litvak Anya M. , Paik Paul K. , Drilon Alexander E. , Socci Nicholas , Poirier John T. , Shen Ronglai , Berger Michael F. , Moreira Andre L. , Travis William D. , Rudin Charles M. , Ladanyi Marc
Published: April 2023

Supplementary Table 5: Detailed summary of NOTCH gene family mutations
Supplemental Figure 4 Dose-dependent inhibition from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Authors: Li Anna , Yang Jin-ji , Zhang Xu-chao , Zhang Zhou , Su Jian , Gou Lan-ying , Bai Yu , Zhou Qing , Yang Zhenfan , Han-Zhang Han , Zhong Wen-Zhao , Chuai Shannon , Zhang Qi , Xie Zhi , Gao Hongfei , Chen Huajun , Wang Zhen , Wang Zheng , Yang Xue-ning , Wang Bin-chao , Gan Bin , Chen Zhi-hong , Jiang Ben-yuan , Wu Si-pei , Liu Si-yang , Xu Chong-rui , Wu Yi-long
Published: April 2023

A-B. Female nu/nu athymic nude mice bearing MET mY1228H (A) and MET mY1226N (B) were treated with increasing dose of XL184 at 0mg/kg/d, 5mg/kg/d, 20mg/kg/d or 60mg/kg/d. Dose-dependent inhibition was observed for both mutations (Non-linear mixed effect model, p<0.0001).
Supplemental methods and figures from Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer
Authors: Skinner Heath D. , Giri Uma , Yang Liang , Woo Sang Hyeok , Story Michael D. , Pickering Curtis R. , Byers Lauren A. , Williams Michelle D. , El-Naggar Adel , Wang Jing , Diao Lixia , Shen Li , Fan You Hong , Molkentine David P. , Beadle Beth M. , Meyn Raymond E. , Myers Jeffrey N. , Heymach John V.
Published: April 2023

Supplemental methods Supplementary Figure 1. Total and phospho-PTK2/FAK is overexpressed in selected radioresistant HNSCC cells compared to radiosensitive cell lines via immunoblot. Supplementary Figure 2. A.) Inhibition of PTK2/FAK expression via stable expression of shRNA to PTK2/FAK in HN31 HNSCC cells. B.) Stable inhibition of PTK2/FAK leads to radiosensitization in vitro. C & D.) The combination of PF562271 and radiation leads to C.) increased γ-H2AX expression and D.) higher levels of G2/M arrest and sub-G1 staining in Fadu HNSCC cells. Supplementary Figure 3. A & B.) PTK2/FAK is highly expressed in a large public database of HNSCC cell lines (www.oncomine.com) (A.) and tumor specimens (TCGA) (B.) compared to other tumor types. Supplementary Table 1. HNSCC cell lines included in RPPA. Supplementary Table 2. Tumor characteristics of the institutional cohorts. Supplementary Table 3. Univariate and multivariate analysis of PTK2/FAK copy number and disease free survival (DFS) in the two institutional cohorts and the Head and Neck Cancer TCGA cohort. NA - not included in the model. HR - Hazard ratio. 95% CI- 95% Confidence Interval. Supplementary Table 4. Tumor characteristics of the HNSCC TCGA cohort.
Supplemental Figure 3 Functional validations of MET Y1248H and D1246N from Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Authors: Li Anna , Yang Jin-ji , Zhang Xu-chao , Zhang Zhou , Su Jian , Gou Lan-ying , Bai Yu , Zhou Qing , Yang Zhenfan , Han-Zhang Han , Zhong Wen-Zhao , Chuai Shannon , Zhang Qi , Xie Zhi , Gao Hongfei , Chen Huajun , Wang Zhen , Wang Zheng , Yang Xue-ning , Wang Bin-chao , Gan Bin , Chen Zhi-hong , Jiang Ben-yuan , Wu Si-pei , Liu Si-yang , Xu Chong-rui , Wu Yi-long
Published: April 2023

A and C. NIH3T3 cells harboring either mouse MET Y1228H or mouse MET D1226N were treated with savolitinib (A) or BMS777607 (C) at indicated concentrations. Viable cells were measured after 72 hours of treatment. Error bars represent standard deviation of biological triplicates. B and D. After treatment with savolitinib (B) and bms777607 (D), cell extracts were immunoblotted to detect total protein levels and phosphorylated forms of key downstream effectors of MET and major cross-talk pathway participants. GAPDH is used as a loading control.
Supplementary Figures S1-S5 from Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Authors: Kong Yan , Sheng Xinan , Wu Xiaowen , Yan Junya , Ma Meng , Yu Jiayi , Si Lu , Chi Zhihong , Cui Chuanliang , Dai Jie , Li Yiqian , Yu Huan , Xu Tianxiao , Tang Huan , Tang Bixia , Mao Lili , Lian Bin , Wang Xuan , Yan Xieqiao , Li Siming , Guo Jun
Published: April 2023

Supplementary Figure S1. Typical staining of CDK4 pathway-related proteins Supplementary Figure S2. Sensitivity of acral melanoma cells to CDK4/6 inhibitors. Supplementary Figure S3. Western blotting assays of total Rb and phosphorylated Rb (pRb) in cell lines after CDK4/6 inhibitor treatments Supplementary Figure S4. Representative images of tumor nodules after the treatments. Supplementary Figure S5. Rb inactivation status in PDX models after AT7519 and PD0332991 treatments.
Appendix 1 from Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance
Authors: Afghahi Anosheh , Timms Kirsten M. , Vinayak Shaveta , Jensen Kristin C. , Kurian Allison W. , Carlson Robert W. , Chang Pei-Jen , Schackmann Elizabeth , Hartman Anne-Renee , Ford James M. , Telli Melinda L.
Published: April 2023

Details of the allele frequencies in the tumor specimens of patient 15 who was found to have a somatic reversion mutation of BRCA1 in the residual tumor tissue
Supplementary Methods, Supplementary Figures 1-10, Supplementary References from CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Authors: Min Irene M. , Shevlin Enda , Vedvyas Yogindra , Zaman Marjan , Wyrwas Brian , Scognamiglio Theresa , Moore Maureen D. , Wang Weibin , Park Susan , Park Spencer , Panjwani Suraj , Gray Katherine D. , Tassler Andrew B. , Zarnegar Rasa , Fahey Thomas J. , Jin Moonsoo M.
Published: April 2023

Figure S1. PTCs with BRAFV600E mutations are associated with ICAM-1 Overexpression; Figure S2. Tumor tissue morphology in ATC patients.; Figure S3. ICAM-1-overexpressing ATC cell lines are more proliferative.; Figure S4. ICAM-1 CAR T cell phenotype characterization; Figure S5. Validation of ICAM-1 CAR T cells used in vivo experiments.; Figure S6. Organ weight changes in ATC xenografted mice after ICAM-1 CAR T treatment.; Figure S7. CAR T cells in ICAM-1 CAR T treated and ATC xenografts.; Figure S8. Establishment of ATC patient-derived xenografts.; Figure S9. CAR T activity is detectable throughout the body.; Figure S10. Correlation between ICAM-1 overexpression in TCGA cancer patient tumor tissues and overall survival.
Supplementary Table 4 from Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Bradley Conor A. , O'Reilly Paul G. , Barrett Helen L. , Cummins Robert , O'Grady Tony , Arthur Ken , Loughrey Maurice B. , Allen Wendy L. , McDade Simon S. , Waugh David J. , Hamilton Peter W. , Longley Daniel B. , Kay Elaine W. , Johnston Patrick G. , Lawler Mark , Salto-Tellez Manuel , Van Schaeybroeck Sandra
Published: April 2023

Supplementary Table 4: Differentially expressed gene list contrasting tumour region of origin between Lymph Node and Invasive Front.
Project outline. from Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Bradley Conor A. , O'Reilly Paul G. , Barrett Helen L. , Cummins Robert , O'Grady Tony , Arthur Ken , Loughrey Maurice B. , Allen Wendy L. , McDade Simon S. , Waugh David J. , Hamilton Peter W. , Longley Daniel B. , Kay Elaine W. , Johnston Patrick G. , Lawler Mark , Salto-Tellez Manuel , Van Schaeybroeck Sandra
Published: April 2023

This Supplementary Figure indicates the project plan
Clinico-pathological information for the 25 patients who were the source of the samples employed in this study from Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer
Authors: Dunne Philip D. , McArt Darragh G. , Bradley Conor A. , O'Reilly Paul G. , Barrett Helen L. , Cummins Robert , O'Grady Tony , Arthur Ken , Loughrey Maurice B. , Allen Wendy L. , McDade Simon S. , Waugh David J. , Hamilton Peter W. , Longley Daniel B. , Kay Elaine W. , Johnston Patrick G. , Lawler Mark , Salto-Tellez Manuel , Van Schaeybroeck Sandra
Published: April 2023

This Supplementary Table indicates the sample source for the study
Supplemental file 1 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
Authors: Castiello Luciano , Sabatino Marianna , Ren Jiaqiang , Terabe Masaki , Khuu Hanh , Wood Lauren V. , Berzofsky Jay A. , Stroncek David F.
Published: April 2023

Excel Spreadsheet listing all the genes belonging to the 8 modules
Figure S1 from Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
Authors: Heery Christopher R. , Palena Claudia , McMahon Sheri , Donahue Renee N. , Lepone Lauren M. , Grenga Italia , Dirmeier Ulrike , Cordes Lisa , Marté Jenn , Dahut William , Singh Harpreet , Madan Ravi A. , Fernando Romaine I. , Hamilton Duane H. , Schlom Jeffrey , Gulley James L.
Published: April 2023

Characterization of rF-brachyury-TRICOM
Supplemental Figure 1 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
Authors: Castiello Luciano , Sabatino Marianna , Ren Jiaqiang , Terabe Masaki , Khuu Hanh , Wood Lauren V. , Berzofsky Jay A. , Stroncek David F.
Published: April 2023

Patient Baseline Parameters and their correlation with Clinical Response measurements
Table S8 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

Raw copy number alterations for all genes in all samples
SI Figures from Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution
Authors: Tang Min , Zhao Rui , van de Velde Helgi , Tross Jennifer G. , Mitsiades Constantine , Viselli Suzanne , Neuwirth Rachel , Esseltine Dixie-Lee , Anderson Kenneth , Ghobrial Irene M. , San Miguel Jesús F. , Richardson Paul G. , Tomasson Michael H. , Michor Franziska
Published: April 2023

Supplementary Figure S1. Demonstration of exponential curves and corresponding linear curves after log-transforming the original data. Supplementary Figure S2. Baseline values for the analysis of disease dynamics during treatment. Supplementary Figure S3. Histograms of the days from treatment cessation until rebound for patients in the VISTA and APEX trials when defining rebound as any value {greater than or equal to} 20% pre-treatment baseline. Supplementary Figure S4. Histograms of the days from treatment cessation until rebound for patients in the VISTA and APEX trials when defining rebound as any value {greater than or equal to} pre-treatment baseline. Supplementary Figure S5. Histograms of the days from treatment cessation until rebound for patients in the VISTA MP and VISTA VMP cohorts when defining rebound as any value {greater than or equal to} 120% pre-treatment baseline. Supplementary Figure S6. Histogram of the deviation between scheduled visit and real visit dates during the trial. Supplementary Figure S7. The predictions of the differentiation hierarchy model of MM. Supplementary Figure S8. Nine representative examples of predictions of the clonal evolution model of MM. Supplementary Figure S9. Early M-protein rebound for the refractory patients in the VISTA and APEX trials.
Combined treatment with osimertinib and vorinostat successively reduces the volumes of xenografts during the therapy. from Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Authors: Tanimoto Azusa , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Yamada Tadaaki , Roca Xavier , Ong S. Tiong , Yano Seiji
Published: April 2023

All values are expressed as mean {plus minus} SE and assessed by one-way ANOVA. *, P < 0.05 osimertinib versus control in A, combination versus osimertinib in B.
Combination of osimertinib and HDAC inhibitors with inhibitory activity of HDAC3 induces apoptosis and up-regulates active BIM. from Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer
Authors: Tanimoto Azusa , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Yamada Tadaaki , Roca Xavier , Ong S. Tiong , Yano Seiji
Published: April 2023

Western blotting of PC-3 and PC-9BIMi2-/- cells treated with gefitinib (1 µmol/L), afatinib (1 µmol/L), osimertinib (1 µmol/L), and/or belinostat (3 µmol/L) for 24 hours. B PC-9BIMi2-/- cells treated with osimertinib (1 µmol/L) and/or RGFP966 (5 µmol/L) for 24 hours.
Figure S5 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

Zygosity estimates for the MCT samples by group
Supplementary Figure 6 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Authors: Lamberts Laetitia E. , Koch Maximillian , de Jong Johannes S. , Adams Arthur L.L. , Glatz Jürgen , Kranendonk Mariëtte E.G. , Terwisscha van Scheltinga Anton G.T. , Jansen Liesbeth , de Vries Jakob , Lub-de Hooge Marjolijn N. , Schröder Carolien P. , Jorritsma-Smit Annelies , Linssen Matthijs D. , de Boer Esther , van der Vegt Bert , Nagengast Wouter B. , Elias Sjoerd G. , Oliveira Sabrina , Witkamp Arjen J. , Mali Willem P.Th.M. , Van der Wall Elsken , van Diest Paul J. , de Vries Elisabeth G.E. , Ntziachristos Vasilis , van Dam Gooitzen M.
Published: April 2023

Intraoperative and Ex Vivo Optical Imaging of Axillary Lymph Nodes.
Figure S2 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma
Authors: Cooke Susanna L. , Ennis Darren , Evers Lisa , Dowson Suzanne , Chan Mei Yen , Paul James , Hirschowitz Lynn , Glasspool Rosalind M. , Singh Naveena , Bell Sarah , Day Elizabeth , Kochman Agata , Wilkinson Nafisa , Beer Philip , Martin Sancha , Millan David , Biankin Andrew V. , McNeish Iain A.
Published: April 2023

Copy number profiles of three highly rearranged SCC genomes. Boxplots of copy number windows corresponding to MYC.
Supplemental Table 3 from Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Authors: Balli David , Rech Andrew J. , Stanger Ben Z. , Vonderheide Robert H.
Published: April 2023

MuSIC-SMG calculations
Supplementary Figure 2 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Authors: Lamberts Laetitia E. , Koch Maximillian , de Jong Johannes S. , Adams Arthur L.L. , Glatz Jürgen , Kranendonk Mariëtte E.G. , Terwisscha van Scheltinga Anton G.T. , Jansen Liesbeth , de Vries Jakob , Lub-de Hooge Marjolijn N. , Schröder Carolien P. , Jorritsma-Smit Annelies , Linssen Matthijs D. , de Boer Esther , van der Vegt Bert , Nagengast Wouter B. , Elias Sjoerd G. , Oliveira Sabrina , Witkamp Arjen J. , Mali Willem P.Th.M. , Van der Wall Elsken , van Diest Paul J. , de Vries Elisabeth G.E. , Ntziachristos Vasilis , van Dam Gooitzen M.
Published: April 2023

Representative Fluorescence Flatbed Scans of Paraffin Blocks of all Patients (N=20) and Macroscopic Segmentation of Fluorescence Tissue Localization and Target-to-Background Ratios (TBR).
Supplemental Figures 1 to 11 from Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Authors: Balli David , Rech Andrew J. , Stanger Ben Z. , Vonderheide Robert H.
Published: April 2023

Supplementary Figure 1. Cumulative distribution of cytolytic index between PAAD and STAD cohorts; Supplementary Figure 2. Enrichment of selected immune related gene sets in cytolytichigh PDA tumors; Supplementary Figure 3. Enrichment of immune related gene sets in cytolytic-high PDA Tumors; Supplementary Figure 4. Cytolytic index associates strongly with expression of Immunome gene sets; Supplementary Figure 5. Expression of copy number alteration-associated and MYC target genes are statistically enriched in cytolytic-low PDA tumors; Supplementary Figure 6. Tumor cellularity/purity estimates do not correlate with mutational load; Supplementary Figure 7. Tumor purity estimates for PDA, stomach adenocarcinoma (STAD) and lung adenocarcinoma (LUAD); Figure S8. No difference in tumor cellularity or purity between cytolytic subtypes in TCGA PAAD cohort; Figure S9. Cytolytic subtypes associate with neoepitope load in stomach (STAD) and lung adenocarcinoma (LUAD); Figure S10. Neoepitope burden does not differ across PDA subtypes; Figure S11. Correlation plots of individual Immune suppression index versus cytolytic index.
Supplement Table 1 from Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Authors: Balli David , Rech Andrew J. , Stanger Ben Z. , Vonderheide Robert H.
Published: April 2023

PAAD patient info
Supplemental Material and Methods from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
Authors: Lamberts Laetitia E. , Koch Maximillian , de Jong Johannes S. , Adams Arthur L.L. , Glatz Jürgen , Kranendonk Mariëtte E.G. , Terwisscha van Scheltinga Anton G.T. , Jansen Liesbeth , de Vries Jakob , Lub-de Hooge Marjolijn N. , Schröder Carolien P. , Jorritsma-Smit Annelies , Linssen Matthijs D. , de Boer Esther , van der Vegt Bert , Nagengast Wouter B. , Elias Sjoerd G. , Oliveira Sabrina , Witkamp Arjen J. , Mali Willem P.Th.M. , Van der Wall Elsken , van Diest Paul J. , de Vries Elisabeth G.E. , Ntziachristos Vasilis , van Dam Gooitzen M.
Published: April 2023

Supplementary Material and Methods / Legends of Supplemental Figures
Supplementary Table 6 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Authors: Becht Etienne , de Reyniès Aurélien , Giraldo Nicolas A. , Pilati Camilla , Buttard Bénédicte , Lacroix Laetitia , Selves Janick , Sautès-Fridman Catherine , Laurent-Puig Pierre , Fridman Wolf Herman
Published: April 2023

Levels of expression of genes related to inflammation, angiogenesis and immunomodulation in CRC cohorts
Supplementary information from Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses
Authors: Vanderstichele Adriaan , Busschaert Pieter , Smeets Dominiek , Landolfo Chiara , Van Nieuwenhuysen Els , Leunen Karin , Neven Patrick , Amant Frédéric , Mahner Sven , Braicu Elena Ioana , Zeilinger Robert , Coosemans An , Timmerman Dirk , Lambrechts Diether , Vergote Ignace
Published: April 2023

Supplementary Methods and References. Supplementary Tables S1-S4. Supplementary Figures S1-S9.
Supplementary Table 5 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Authors: Becht Etienne , de Reyniès Aurélien , Giraldo Nicolas A. , Pilati Camilla , Buttard Bénédicte , Lacroix Laetitia , Selves Janick , Sautès-Fridman Catherine , Laurent-Puig Pierre , Fridman Wolf Herman
Published: April 2023

Consensus Molecular Subgroup-level statistics on each MCP-counter abundance estimates
Supplementary Table 3 from Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Authors: Becht Etienne , de Reyniès Aurélien , Giraldo Nicolas A. , Pilati Camilla , Buttard Bénédicte , Lacroix Laetitia , Selves Janick , Sautès-Fridman Catherine , Laurent-Puig Pierre , Fridman Wolf Herman
Published: April 2023

Samples from the Cancer Cell Line Encyclopedia
Supplementary Figures from A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice
Authors: Tran Thi , Diniz Mariana O. , Dransart Estelle , Gey Alain , Merillon Nathalie , Lone Yu Chun , Godefroy Sylvie , Sibley Craig , Ferreira Luis CS , Medioni Jacques , Oudard Stephane , Johannes Ludger , Tartour Eric
Published: April 2023

Supplementary Fig 1 : Establishment of a Her2-HLA-A2 B16 tumor model in HLA-A2 TG mice. Supplementary Fig 2 : STxB-E75 combined with GM-CSF and CpG induced potent anti-Her2 CD8+T cells. Supplementary Fig 3 : Presence of intratumoral anti-E75 CD8+T cells after vaccination Supplementary Fig 4 : Inverse correlation between hHer2 levels and HLA-A2 expression in various tumor cell lines.
Supplementary Tables from Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action
Authors: Yu Ziyang , He Suqin , Wang Dannie , Patel Hitisha K. , Miller Chris P. , Brown Jeffrey L. , Hattersley Gary , Saeh Jamal C.
Published: April 2023

Supplementary Table S1. List of targets in the spectrum screen Supplementary Table S2. Characteristics of the breast cancer PDX models Supplementary Table S3. List of genes upregulated by more than 2-fold in RAD140-treated HBCx-22 xenografts
Supplementary Table Results from Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
Authors: Lynch James T. , Polanska Urszula M. , Delpuech Oona , Hancox Urs , Trinidad Antonio G. , Michopoulos Filippos , Lenaghan Carol , McEwen Robert , Bradford James , Polanski Radek , Ellston Rebecca , Avivar-Valderas Alvaro , Pilling James , Staniszewska Anna , Cumberbatch Marie , Critchlow Susan E. , Cruzalegui Francisco , Barry Simon T.
Published: April 2023

Supplementary Table results
Table S8 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
Authors: Sun Jie , Meng Hua , Yao Lu , Lv Meng , Bai Jian , Zhang Jianguang , Wang Lientu , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

Survival in Molecular Subgroups
Supplementary Table Methods from Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
Authors: Lynch James T. , Polanska Urszula M. , Delpuech Oona , Hancox Urs , Trinidad Antonio G. , Michopoulos Filippos , Lenaghan Carol , McEwen Robert , Bradford James , Polanski Radek , Ellston Rebecca , Avivar-Valderas Alvaro , Pilling James , Staniszewska Anna , Cumberbatch Marie , Critchlow Susan E. , Cruzalegui Francisco , Barry Simon T.
Published: April 2023

Supplementary Table Methods
Supplementary Figures 1-9 from Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
Authors: Lynch James T. , Polanska Urszula M. , Delpuech Oona , Hancox Urs , Trinidad Antonio G. , Michopoulos Filippos , Lenaghan Carol , McEwen Robert , Bradford James , Polanski Radek , Ellston Rebecca , Avivar-Valderas Alvaro , Pilling James , Staniszewska Anna , Cumberbatch Marie , Critchlow Susan E. , Cruzalegui Francisco , Barry Simon T.
Published: April 2023

Supplemtary figures 1-9
Table S4 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients
Authors: Sun Jie , Meng Hua , Yao Lu , Lv Meng , Bai Jian , Zhang Jianguang , Wang Lientu , Ouyang Tao , Li Jinfeng , Wang Tianfeng , Fan Zhaoqing , Fan Tie , Lin Benyao , Xie Yuntao
Published: April 2023

Two Germline Pathogenic Mutations
Table S2 from Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Authors: Hijioka Susumu , Hosoda Waki , Matsuo Keitaro , Ueno Makoto , Furukawa Masayuki , Yoshitomi Hideyuki , Kobayashi Noritoshi , Ikeda Masafumi , Ito Tetsuhide , Nakamori Shoji , Ishii Hiroshi , Kodama Yuzo , Morizane Chigusa , Okusaka Takuji , Yanagimoto Hiroaki , Notohara Kenji , Taguchi Hiroki , Kitano Masayuki , Yane Kei , Maguchi Hiroyuki , Tsuchiya Yoshiaki , Komoto Izumi , Tanaka Hiroki , Tsuji Akihito , Hashigo Syunpei , Kawaguchi Yoshiaki , Mine Tetsuya , Kanno Atsushi , Murohisa Go , Miyabe Katsuyuki , Takagi Tadayuki , Matayoshi Nobutaka , Yoshida Tsukasa , Hara Kazuo , Imamura Masayuki , Furuse Junji , Yatabe Yasushi , Mizuno Nobumasa
Published: April 2023

Supplementary Table S2. Breakdown of responses to chemotherapy regimens for NET-G3 (16 cases)
FigureS1 from Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Authors: Hijioka Susumu , Hosoda Waki , Matsuo Keitaro , Ueno Makoto , Furukawa Masayuki , Yoshitomi Hideyuki , Kobayashi Noritoshi , Ikeda Masafumi , Ito Tetsuhide , Nakamori Shoji , Ishii Hiroshi , Kodama Yuzo , Morizane Chigusa , Okusaka Takuji , Yanagimoto Hiroaki , Notohara Kenji , Taguchi Hiroki , Kitano Masayuki , Yane Kei , Maguchi Hiroyuki , Tsuchiya Yoshiaki , Komoto Izumi , Tanaka Hiroki , Tsuji Akihito , Hashigo Syunpei , Kawaguchi Yoshiaki , Mine Tetsuya , Kanno Atsushi , Murohisa Go , Miyabe Katsuyuki , Takagi Tadayuki , Matayoshi Nobutaka , Yoshida Tsukasa , Hara Kazuo , Imamura Masayuki , Furuse Junji , Yatabe Yasushi , Mizuno Nobumasa
Published: April 2023

Supplementary figureS1 - Representative cases of pancreatic NEN-G3
Figure S7 from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

Post-transcriptional regulation of Mcl-1 expression.
Figure S1 from Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation
Authors: Kapoor Shivani , Natarajan Karthika , Baldwin Patrick R. , Doshi Kshama A. , Lapidus Rena G. , Mathias Trevor J. , Scarpa Mario , Trotta Rossana , Davila Eduardo , Kraus Manfred , Huszar Dennis , Tron Adriana E. , Perrotti Danilo , Baer Maria R.
Published: April 2023

Quizartinib, sorafenib, crenolanib and gilteritinib cytotoxicity in cell lines with FLT3-ITD or FLT3-WT
Supplementary Tables S1, S2 and Figures S1-S5 from A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
Authors: Ma Cynthia X. , Suman Vera , Goetz Matthew P. , Northfelt Donald , Burkard Mark E. , Ademuyiwa Foluso , Naughton Michael , Margenthaler Julie , Aft Rebecca , Gray Richard , Tevaarwerk Amye , Wilke Lee , Haddad Tufia , Moynihan Timothy , Loprinzi Charles , Hieken Tina , Barnell Erica K. , Skidmore Zachary L. , Feng Yan-Yang , Krysiak Kilannin , Hoog Jeremy , Guo Zhanfang , Nehring Leslie , Wisinski Kari B. , Mardis Elaine , Hagemann Ian S. , Vij Kiran , Sanati Souzan , Al-Kateb Hussam , Griffith Obi L. , Griffith Malachi , Doyle Laurence , Erlichman Charles , Ellis Matthew J.
Published: April 2023

Fig S1 Study Flowchart Fig S2 PIK3CA somatic mutation pattern Fig S3 Lack of apoptotic effect by anastrozole monotherapy (C1D1) and in combination with MK-2206 (C1D17 and surgery) Fig S4 CDH1 somatic mutation pattern Fig S5 ESR1 somatic mutation pattern
Supplementary figures, table legends, Table S1, S9 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Authors: Tarantelli Chiara , Gaudio Eugenio , Arribas Alberto J. , Kwee Ivo , Hillmann Petra , Rinaldi Andrea , Cascione Luciano , Spriano Filippo , Bernasconi Elena , Guidetti Francesca , Carrassa Laura , Pittau Roberta Bordone , Beaufils Florent , Ritschard Reto , Rageot Denise , Sele Alexander , Dossena Barbara , Rossi Francesca Maria , Zucchetto Antonella , Taborelli Monica , Gattei Valter , Rossi Davide , Stathis Anastasios , Stussi Georg , Broggini Massimo , Wymann Matthias P. , Wicki Andreas , Zucca Emanuele , Cmiljanovic Vladimir , Fabbro Doriano , Bertoni Francesco
Published: April 2023

Supplementary figures, table legends, Table S1, S9 Figure S1. In vitro antitumor activity of the dual PI3K/mTOR inhibitor apitolisib and its correlation with PQR309. Figure S2. Antitumor In vivo activity of PQR309 in the treatment of RI-1 and SU-DHL-6 xenograft model. Figure S3. Apoptosis is induced by co-treatment of PQR309 with venetoclax or panobinostat in primary cells and in the DLBCL SU-DHL-6 cell line. Figure S4. Specific baseline gene expression signatures are associated with higher or lower sensitivity to PQR309. Figure S5. In vitro antitumor activity of the PI3KÃ¯Â�Â¤ inhibitor idelalisib and its correlation with PQR309. Figure S6. PQR309 induced decrease in phosphorylation of AKT-Ser473 and p70S6K-Thr389 in DLBCL cell lines. Figure S7. PQR309 reduces AKT-Ser473 phosphorylation in lymphoma cell lines. Figure S8. Transcriptional expression signature of ABC DLBCL cell lines induced by PQR309. Figure S9. ABC and GCB DLBCL PQR309-treated signatures were highly overlapping. Figure S10. Transcript expression levels of PQR309-treated samples. Figure S11. Changes in protein phosphorylation and RNA expression differently contribute to PQR309 affected biologic pathways in ABC DLBCL. Figure S12. PQR309 can largely regulate the same genes affected by the BTK inhibitor ibrutinib, the PI3KÃ¯Â�Â¤ idelalisib, the dual PI3KÃ¯Â�Â§/Ã¯Â�Â¤ inhibitor duvelisib (A), the dual PI3KÃ¯Â�Â¡/Ã¯Â�Â¤ inhibitor AZD8835 or the AKT inhibitor AZD5363 (B). Figure S13. BCR pathway signature is similarly affected after ibrutinib, idelalisib and duvelisib treatments in ABC DLBCL cell lines. Figure S14. The dual PI3K/mTOR inhibitor PQR309 and the PIM inhibitor AZD1208 synergize in DLBCL cell lines. Supplementary Table 1. List of phosphoresidues investigated by Carna Bioscience to perform RPPA analysis. Supplementary Table 9. Transcripts differentially expressed in ABC DLBCL cell lines treated with ibrutinib (A), idelalisib (B) or duvelisib (C) versus DMSO.
Supplementary Figure Legends from A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer
Authors: Ma Cynthia X. , Suman Vera , Goetz Matthew P. , Northfelt Donald , Burkard Mark E. , Ademuyiwa Foluso , Naughton Michael , Margenthaler Julie , Aft Rebecca , Gray Richard , Tevaarwerk Amye , Wilke Lee , Haddad Tufia , Moynihan Timothy , Loprinzi Charles , Hieken Tina , Barnell Erica K. , Skidmore Zachary L. , Feng Yan-Yang , Krysiak Kilannin , Hoog Jeremy , Guo Zhanfang , Nehring Leslie , Wisinski Kari B. , Mardis Elaine , Hagemann Ian S. , Vij Kiran , Sanati Souzan , Al-Kateb Hussam , Griffith Obi L. , Griffith Malachi , Doyle Laurence , Erlichman Charles , Ellis Matthew J.
Published: April 2023

Supplementary Figure Legends S1-S5
Video - from Optoacoustic Detection of Early Therapy-Induced Tumor Cell Death Using a Targeted Imaging Agent
Authors: Xie Bangwen , Tomaszewski Michal R. , Neves André A. , Ros Susana , Hu De-En , McGuire Sarah , Mullins Stefanie R. , Tice David , Sainson Richard C.A. , Bohndiek Sarah E. , Wilkinson Robert W. , Brindle Kevin M.
Published: April 2023

Supplementary videos. Representative reconstructed 3D rendering of a Colo205 tumor 3 h after injection of 0.2 µmole/kg of C2Am-750. Signals from C2Am-750, oxygenated hemoglobin (HbO2), deoxygenated hemoglobin (Hb) are shown in green, red and blue respectively.
3D reconstruction of optoacoustic images of a MEDI3039-treated Colo205 tumor before injection of C2Am-750 from Optoacoustic Detection of Early Therapy-Induced Tumor Cell Death Using a Targeted Imaging Agent
Authors: Xie Bangwen , Tomaszewski Michal R. , Neves André A. , Ros Susana , Hu De-En , McGuire Sarah , Mullins Stefanie R. , Tice David , Sainson Richard C.A. , Bohndiek Sarah E. , Wilkinson Robert W. , Brindle Kevin M.
Published: April 2023

Supplementary video. Representative reconstructed 3D rendering of a Colo205 tumor before injection of 0.2 µmole/kg of C2Am-750. Signals from C2Am-750, oxygenated hemoglobin (HbO2), deoxygenated hemoglobin (Hb) are shown in green, red and blue respectively.
Supplementary Table 5 from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Disease free survival (DFS) and overall survival (OS) analysis according to AR mRNA expression levels in BC subtypes
Supplementary Table 4 from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Data sets for gene-expression analysis with patients' and tumours' characteristics from the neoadjuvant studies
Supplementary legend from Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues
Authors: Dai Charles , Chung Yoon-Mi , Kovac Evan , Zhu Ziqi , Li Jianneng , Magi-Galluzzi Cristina , Stephenson Andrew J. , Klein Eric A. , Sharifi Nima
Published: April 2023

Supplementary legend
Supplementary Table 3 from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

Data sets for gene-expression analysis with patients' and tumours' characteristics
Supplementary Figure 2 from Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues
Authors: Dai Charles , Chung Yoon-Mi , Kovac Evan , Zhu Ziqi , Li Jianneng , Magi-Galluzzi Cristina , Stephenson Andrew J. , Klein Eric A. , Sharifi Nima
Published: April 2023

Figure S2. Primary prostate tissue samples demonstrate no uridine 5'-diphospho-glucuronosyltransferase (UGT) activity when cultured ex vivo in Tunl. A positive control consisting of grossly homogenized LNCaP xenograft tissues was included for comparison. Error bars represent the SD of biological triplicates.
Supplementary Table 1 from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

REMARK scores of eligible studies for clinical meta-analysis
Supplementary Figure 1 from Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues
Authors: Dai Charles , Chung Yoon-Mi , Kovac Evan , Zhu Ziqi , Li Jianneng , Magi-Galluzzi Cristina , Stephenson Andrew J. , Klein Eric A. , Sharifi Nima
Published: April 2023

Figure S1. Validation of a mixed substrate approach to track 5α-reductase activity by LC-MS/MS.
Supplementary Figure Figure 1A_1B from The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Authors: Bozovic-Spasojevic Ivana , Zardavas Dimitrios , Brohée Sylvain , Ameye Lieveke , Fumagalli Debora , Ades Felipe , de Azambuja Evandro , Bareche Yacine , Piccart Martine , Paesmans Marianne , Sotiriou Christos
Published: April 2023

PRISMA flow chart for studies involved in clinical meta-analysis Study flow chart for gene expression pooled analysis
Supplementary material from Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues
Authors: Balakrishnan Ashwini , Goodpaster Tracy , Randolph-Habecker Julie , Hoffstrom Benjamin G. , Jalikis Florencia G. , Koch Lisa K. , Berger Carolina , Kosasih Paula L. , Rajan Anusha , Sommermeyer Daniel , Porter Peggy L. , Riddell Stanley R.
Published: April 2023

Supplementary Figure 1: IHC staining using previously published ROR1 antibodies on control and ROR1 transfected K562 cells, CLL and MCL lymph nodes and tonsil tissue. Supplementary Figure 2: Development of mAb 6D4 Supplementary Figure 3: Representative images of IHC scoring of ROR1+ tumors. Supplementary Figure 4: ROR1 expression in pancreatic adenocarcinomas using mAb 6D4. Supplementary Figure 5: ROR1 staining in absent in normal human cerebrum, cerebellum, heart, lung, spleen and liver. Scale bar represents 100μm. Supplementary Figure 6: Immunoblot validation of ROR1 expression in normal tissues. Supplementary Figure 7: Transcript expression of Ror1 variant 1 in CLL PBMC, differentiated adipocytes and normal human gastrointestinal tissues.
Supplementary Figure S3 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

The stability of unsupervised hierarchical clustering of candidate biomarkers A: 23 markers in PBMC samples, B: 22 markers in ascites samples. Healthy controls (HH), benign ovarian tumours (BN), borderline ovarian tumour (BT) and malignant cases (SER: serous; END: endometrioid; CC: clear cell; MU: mucinous). The stability was estimated by pvclust package in R (see method).
Supplementary Table S5 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
Authors: Guedes Liana B. , Almutairi Fawaz , Haffner Michael C. , Rajoria Gaurav , Liu Zach , Klimek Szczepan , Zoino Roberto , Yousefi Kasra , Sharma Rajni , De Marzo Angelo M. , Netto George J. , Isaacs William B. , Ross Ashley E. , Schaeffer Edward M. , Lotan Tamara L.
Published: April 2023

Demographic and clinical characteristics of eligible patients undergoing radical prostatectomy in post-biochemical recurrence cohort
Supplementary Figure S1 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
Authors: Chatterjee Jayanta , Dai Wei , Aziz Nor Haslinda Abd , Teo Pei Yun , Wahba John , Phelps David L. , Maine Christian J. , Whilding Lynsey M. , Dina Roberto , Trevisan Giorgia , Flower Kirsty J. , George Andrew J.T. , Ghaem-Maghami Sadaf
Published: April 2023

REMARK flow diagram to show the patient groups used in each part of the study. Groups have been ringed in colour to denote in which part of the study these data were used. Of the 71 EOC patients who donated blood and/or ascites, eight donated only ascites.